Icodextrin Peritoneal Dialysis Solution

Abstract

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.

Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The June 2003 monograph topics are aprepitant, gemifloxacin, desirudin for injection, gatifloxacin ophthalmic solution, and pegvisomant. The DUE is on aprepitant.

Get full access to this article

View all access options for this article.

References

Extraneal package literature. Baxter Healthcare Corporation; January 2003.

Plum

Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis.

Am J Kidney Dis. 2002; 39: 862–71.

Moberly

J.B.

Pharmacokinetics of icodextrin in peritoneal dialysis patients.

Kidney Int. 2002; 62(suppl 1): S23–33.

Posthuma

Icodextrin use in CCPD patients during peritonitis: Ultrafiltration and serum disaccharide concentrations.

Nephrol Dial Transplant. 1998; 13: 2341–4.

Wolfson

A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis.

Am J Kidney Dis. 2002; 40: 1055–65.

Diaz-Buxo

J.A.

Potential hazards of polyglucose.

ASAIO J. 2001; 47: 602–7.

Guo

Early quality of life benefits of icodextrin in peritoneal dialysis.

Kidney Int. 2002; 62(suppl 1): S72–9.

Mistry

C.D.

A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD.

Kidney Int. 1994; 46: 496–503.

Woodrow

Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis.

Nephrol Dial Tranplant. 1999; 14: 1530–5.

10.

Woodrow

Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis.

Nephrol Dial Transplant. 2000; 15: 862–6.

11.

Posthuma

Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis.

Perit Dial Int. 2000; 20(suppl 1): S106–13.

12.

Posthuma

Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance.

Nephrol Dial Transplant. 1997; 12: 550–3.

13.

Johnson

D.W.

Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload.

BMC Nephrology. 2001; 2: 2.

14.

Oyibo

S.O.

Blood glucose overestimation in diabetic patients on continuous ambulatory peritoneal dialysis for end-stage renal disease.

Diabet Med. 2002; 19: 693–6.

15.

Mehmet

Important causes of hypoglycaemia in patients with diabetes on peritoneal dialysis.

Diabet Med. 2001; 18: 679–82.

16.

Schoenicke

Dialysis with icodextrin interferes with measurement of serum α-amylase activity.

Nephrol Dial Transplant. 2002; 17: 1988–92.

17.

Gokal

Metabolic and laboratory effects of icodextrin.

Kidney Int. 2002; 62(suppl 1): S62–71.

18.

de Boer

A.W.

Clinical experience with icodextrin in children: Ultrafiltration profiles and metabolism.

Pediatr Nephrol. 2000; 14: 21–4.

19.

Divino Filho

J.C.

Allergic reactions to icodextrin in patients with renal failure [letter].

Lancet. 2000; 355: 1364.

20.

Valance

Icodextrin cutaneous hypersensitivity: Report of 3 psoriasiform cases.

Arch Dermatol. 2001; 137: 309–10.

21.

Goldsmith

Allergic reactions to the polymeric glucose-based peritoneal dialysis fluid icodextrin in patients with renal failure.

Lancet. 2000; 355: 897.

22.

Kanny

Hypersensitivity to icodextrin.

Allergy. 2002; 57: 60–1.

23.

Fletcher

Icodextrin allergy in a peritoneal dialysis patient.

Nephrol Dial Transplant. 1998; 13: 2656–8.

24.

Al-Hoqail

I.A.

, Crawford

R.I.

Acute generalized exanthematous pustulosis induced by icodextrin [letter].

Br J Dermatol. 2001; 145: 1022–36.

25.

Queffeulou

Allergy to icodextrin [letter].

Lancet. 2000; 356: 75.

26.

Gradden

C.W.

Peritoneal dialysis: New developments and new problems.

Diabet Med. 2001; 18: 360–3.

27.

MacGinley

Relapsing culture-negative peritonitis in peritoneal dialysis patients exposed to icodextrin solution.

Am J Kidney Dis. 2002; 40: 1030–5.

28.

Tintillier

Transient sterile chemical peritonitis with icodextrin: Clinical presentation, prevalence, and literature review.

Perit Dial Int. 2002; 22: 534–7.

29.

Del Rosso

A new form of acute adverse reaction to icodextrin in a peritoneal dialysis patient [letter].

Nephrol Dial Transplant. 2000; 15: 927–8.

30.

Fiedler

Does peritoneal dialysis predispose a diabetic patient to icodextrin-induced peritonitis? [letter].

Nephrol Dial Transplant. 2002; 17: 1708–9.

31.

Lin

Y-F

. Stability of cefazolin sodium in icodextrin-containing peritoneal dialysis solution [letter]. Am J Health-Syst Pharm. 2002; 59: 2362–3.